Proprotein convertase subtilisin like/kexin type 9 (PCSK9) is a protein involved in the LDL cholesterol metabolism. The single nucleotide polymorphism (SNP) rs11591147 has been associated with lower LDL cholesterol and a lower risk of coronary heart disease. Since PCSK9 has high affinity to the LDL receptor, inhibiting PCSK9 is a testable therapeutic target for lipid lowering therapy. Currently, several approaches to inhibit PCSK9 are under development, but it is unknown what the effects of those inhibitors will be on cognition or non-cardiovascular clinical events. In this study we assessed the association between rs11591147 and cognitive performance, activities of daily living (ADL), and non-cardiovascular clinical events within 5777 participants of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
Introduction
Elevated plasma concentration of low-density lipoprotein (LDL) cholesterol is a major causal risk factor for cardiovascular disease. Lowering LDL cholesterol levels is one of the primary goals of therapy in its prevention and treatment (1) . Present lipid lowering therapy mainly depends on treatment with HMG-CoA reductase inhibitors (statins), but new lipid lowering drugs are under development that can decrease circulating lipid levels even more (2) . A promising new therapeutic target for lipid lowering therapy is proprotein convertase subtilisin-like/kexin type 9 (PCSK9), a protein involved in LDL cholesterol metabolism (3) (4) (5) . PCSK9 modulates plasma LDL cholesterol levels by promoting the degradation of LDL receptors (LDLR) (6) .
Several "loss of function" and "gain of function" mutations have been described in the PCSK9 gene (4) . Within the Atherosclerosis Risk in Communities (ARIC) Study "loss of function" mutations, for example rs11591147, were associated with lower LDL cholesterol levels through increased LDL receptor levels, resulting in a lower prevalence of peripheral arterial disease, and a reduced risk of coronary heart disease (7, 8) . A recent meta-analysis showed 12% lower LDL cholesterol levels and 28% lower ischemic heart disease risk among carriers of the rs11591147 mutation in the PCSK9 gene (9) .
On the other hand, PCSK9 may be involved in processes associated with neurodegenerative disorders like Alzheimer's disease. A Canadian study found a two-fold increased expression of the PCSK9 in the human frontal cortex of autopsy-confirmed Alzheimer's disease cases compared with age-matched controls (10) . Furthermore, men carrying either the rs2483205-C, rs483462-A, or rs662145-T allele showed a significant increased risk for Alzheimer's disease.
However, those single nucleotide polymorphisms (SNPs) are not known to be associated with LDL cholesterol levels or with cardiovascular disease risk.
by guest, on November 9, 2017 www.jlr.org
Downloaded from
Nowadays several approaches to inhibit PCSK9 are under development, but it is not know if those inhibitors will have influences on cognitive performance or clinical events. At old age cholesterol levels are not associated with cognitive performance and it has previously been shown in PROSPER that pravastatin therapy in old age did not affect cognitive decline over median follow-up of 3.2 years (11, 12) . However, to investigate whether lipid lowering via PCSK9 inhibition might have other clinical effects besides lipid lowering, we assessed the relation between lower LDL levels associated with genetic variation within the PCSK9 SNP rs11591147 and cognitive function, ADL, and non-cardiovascular clinical events in an elderly population where these events occur frequently.

Methods
Study population
All data come from the PROspective Study of Pravastatin in the Elderly at Risk for vascular disease (PROSPER). Detailed descriptions of PROSPER have been published elsewhere (13, 14) .
Briefly, PROSPER was an investigator-driven, prospective multi-national randomized placebocontrolled trial to assess whether treatment with pravastatin reduces the risk of major vascular events in the elderly. Between December 1997 and May 1999, subjects in Scotland (Glasgow), Ireland (Cork) and the Netherlands (Leiden) were screened and enrolled. Men and women aged 70-82 years were recruited if they had pre-existing vascular disease or were at increased risk for such disease because of smoking, diabetes, or hypertension. A total number of 5804 subjects were randomly assigned to pravastatin or placebo. The protocol of the PROSPER study was approved by the Medical Ethics Committees of each participating institution. Written informed consent was obtained from all participating subjects.
Endpoints
Mean follow-up duration was 3.2 years (range 2.8-4.0) and participants were reviewed every 3 months. During those visits all endpoints were adjudicated by a study Endpoint Committee. The primary outcome in PROSPER was the combined endpoint of definite or suspected death from coronary heart disease, non-fatal myocardial infarction, and fatal or non-fatal stroke.
Furthermore several non-cardiovascular clinical events were recorded. Cancer incidence was a tertiary study endpoint. Infections and diabetes were reported as serious adverse effects. Since the association between PCSK9 and cardiovascular events has been investigated previously in by guest, on November 9, 2017 www.jlr.org
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PROSPER the focus in the present paper was on non-cardiovascular events, functional status, and cognitive performance.
Cognitive performance and activities of daily living (ADL)
The Mini-Mental State Examination (MMSE) was used to measure global cognitive performance. participants, therefore we performed the analyses with their individually varying time-point but report the results for the mean of these time-points (42 months). The pre-randomized measurement was discarded in the analysis to preclude possible learning effects.
Genotyping
Rs11591147 of the PCSK9 gene was genotyped previously in PROSPER using Taq Man® SNPs genotyping assay (Applied Biosystems, Foster City, CA, United States). A detailed description of the genotyping has been published elsewhere (16) . Rs11591147 genotyping succeeded in 5777 of the 5804 PROSPER participants. ApoE phenotype was determined on plasma samples by western blotting, using the method of Havekes et al. (17) .
To assess the association between other PCSK9 SNPs and cholesterol levels, cognitive performance and clinical events we used data of the PHArmacogenetic study of Statins in the Elderly at risk (PHASE), a genome-wide association study (GWAS) in the PROSPER participants (18) . The GWAS was conducted using the Illumina 660-Quad beadchips following manufacturer's instructions. After a stringent quality control 557,192 SNPs were available for analysis. To maximize the availability of genetic data and coverage of the genome, imputation up to 2.5 million autosomal CEPH HapMap SNPs was performed with MACH imputation software based on the Hapmap built II release 23. Detailed descriptions of the PHASE project have been published elsewhere (18) . PCSK9 SNPs were selected from the GWAS using PLINK software version 1.07 (http://pngu.mgh.harvard.edu/purcell/plink/) (19) .
Statistical analysis
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Cross-sectional associations between rs11591147 and cognitive function were assessed using a general linear model adjusted for age, sex, country, education, ApoE phenotype and where appropriate version of test used. Repeated cross-sectional associations with cognitive function were assessed with a linear mixed model for repeated measurements and were additionally adjusted for follow-up time. Cross-sectional associations between rs11591147 and history of clinical events were assessed with logistic regression analysis, which was adjusted for age, sex, and country. Longitudinal associations were assessed with Cox regression and were additionally adjusted for pravastatin use. Power calculation was performed using Quanto version 1.2.4, May 2009. The study had 99% power to detect a 2% increased incidence of diabetes by the rs11591147 variant, assuming a 5% incidence rate in the rs11591147 wildtype carriers. PASW statistics software (version 17.0.2, SPSS Inc., Chicago, IL) was used for all statistical analyses. Pvalues <0.05 were considered statistically significant. Table 1 shows the baseline characteristics of study subjects, stratified by country of origin. The mean age of all subjects was 75.3 years and about 50% of the participants were female. The association between the PCSK9 SNP rs11591147 and lipoprotein levels and vascular events has previously been described (16) . To summarize these findings, carriers of one rs11591147 variant had 10% lower LDL cholesterol levels (p=3.62 x 10 -12 ) ( Table 2 ) and a non-significant 9% reduced risk of vascular disease (16). Table 2 shows the association between rs11591147 and cognitive performance and functional status. There were no associations between rs11591147 and cognitive performance and functional status, either at baseline or during follow-up (all p>0.1).
Next, we assessed the association between rs11591147 and history of diabetes and hypertension at baseline. Carrying a variant of rs11591147 was not associated with a history of diabetes or hypertension (both p>0.4) ( Table 3) . Also during follow-up, there was no association between rs11591147 and the incidence of cancer, diabetes and infections (Table 3) .
To cover the whole PCSK9 gene, we also assessed the association between other PCSK9 tag SNPs (rs2094470, rs2479415, rs7525649, rs17111495, rs10888896, rs4927193, rs2479411, rs499718, rs10888897, rs529787, rs562556, rs615563, rs10465832, rs505151, rs662145, rs9326034) and cholesterol levels, cognitive performance, functional status, and clinical events using data of the PHASE study (18) . Three SNPs, rs2479415, rs2182833, and rs11206514, were associated with LDL cholesterol levels (all p<0.01). However, none of these SNPs were also associated with cognitive performance, functional status, or non-cardiovascular clinical events (supplementary tables 1-2). Also, when we combined the PCSK9 SNPs into haplotypes there were no associations by guest, on November 9, 2017 www.jlr.org
between the haplotypes, cholesterol levels, cognitive performance, functional status, or clinical events (data not shown).
Discussion
In this study we assessed the association between the PCSK9 SNP rs11591147, cognitive performance, functional status and non-cardiovascular clinical events in the PROSPER study. No association between rs11591147 and cognitive performance, functional status or non-vascular clinical events was observed. As the SNP was significantly associated with lower cholesterol and with cardiovascular disease protection (7, 9, 16) , these data do not lend arguments that drugs inhibiting PCSK9 will have other (adverse) effects.
The association between the PCSK9 SNP rs11591147 and lipid levels and vascular disease risk has been investigated previously in PROSPER (16) . In this analysis carriers of the rare variant of rs11591147 had significantly 10% lower LDL cholesterol levels (P<0.001). These lower LDL cholesterol levels are well in line with the findings of a meta-analysis including seven general population studies with a total of 1,639 carriers of the rs11591147 minor allele and 59,298 noncarriers (9) . In this meta-analysis, rs11591147 was associated with 12% lower LDL cholesterol levels in carriers. The same article also reported a meta-analysis combining studies which of β-amyloid deposition in brain autopsy studies (11) . Since PCSK9 is involved in the cholesterol metabolism this raises the question if PCSK9 is also associated with cognitive function. A Canadian study investigated the relation between PCSK9 and Alzheimer's disease. In this study variations in rs2483205, rs483462, and rs662145 were associated with an increased Alzheimer's disease risk (10) . However, those SNPs are not known to be associated with cholesterol levels or in linkage disequilibrium with one of our SNPs associated with LDL cholesterol. A study with Japanese Alzheimer's disease patients found no association between the PCSK9 SNPs rs11583680 and rs662145 and Alzheimer's disease (20) . In our study, rs11591147 was not associated with cognitive performance.
Since PCSK9 has high affinity for the LDLR, inhibiting PCSK9 might be a promising therapeutic target for lipid lowering therapy in addition to statin therapy. Several approaches to inhibit PCSK9 are currently under development, but it is unknown what the influences of those inhibitors will be on cognitive function or non-cardiovascular events (2). In our study rs11591147, associated with LDL cholesterol levels, did not affect cognitive performance, functional status, or non-cardiovascular clinical events. Based on our results one may expect that drugs inhibiting PCSK9 (21) (22) (23) , to an extend comparable to the rs11591147 mutation, administered to an age group 70 to 82 years with a history or increased risk of cardiovascular disease are not likely to affect cognitive performance. This suggests that cholesterol lowering by PCSK9 inhibition may be a valid and safe way to reduce cardiovascular disease risk. However, as the inhibitors in development may cause larger LDL cholesterol reductions compared to the rs11591147 mutation, definite conclusions about the adverse effects of cholesterol lowering due to PCSK9 inhibition can not be assessed by this study.
One of the strengths of our study is our population size. We have prospective data of over 5000 subjects on lipid parameters, cognitive function, and clinical endpoints. Also we have a follow-up of 42 months with very little lost to follow-up. Furthermore, our population is an appropriate study population to measure cognitive function, since only subjects with a MMSE above 24 points were eligible for participation, which makes it a homogenous study group suitable for investigating cognitive function.
A possible limitation of our study is the limited power to detect subtle differences. Although the PROSPER study is one of the largest studies to investigate the association between genetic variations and lipid levels, cognitive function, and clinical events, we do not have infinite power to detect small effects. But we assume that it is unrealistic that we have missed clinically relevant effects. Another possible limitation is the ceiling effect of the ADL measurements. This may have restricted our ability to find significant associations between the PCSK9 mutation and ADL performance. However, previous analysis on apolipoprotein E genotype have proven that the PROSPER study is suitable for investigating genetic influences on cognition and ADL (24) . A last possible limitation is the selection of the PROSPER participants. Participants were recruited when they had existing vascular disease or increased risk of such disease (13) . Individuals especially susceptible to the mutation leading not only to low LDL cholesterol but also protective for cardiovascular disease may have been under represented in our study.
In conclusion, it has previously been shown that the PCSK9 SNP rs11591147 is associated with lower LDL cholesterol levels and lower cardiovascular risk. In our study we failed to find associations between the variant and cognitive phenotypes. The implication of our finding is that it is unlikely that medication lowering LDL cholesterol via inhibiting PCSK9 to an extent comparable to the effect of the mutation in our study population, will affect cognitive performance, functional status, or non-cardiovascular clinical events. Estimates and p-values at baseline were assessed with general linear model adjusted for sex, age, and country. Analyses on cognition were additional adjusted for education, APOE genotype, and were appropriate, version of test used. Repeated cross-sectional estimates and p-values were assessed with linear mixed model and additional adjusted for follow-up time.
